** Shares of cancer therapy developer Oncternal Therapeutics
hit record low, last down 59.32% at $1.69
** Co says it will discontinue its trials studying its experimental cancer therapies ONCT-534 and ONCT-808 and will explore strategic alternatives
** In early stage trial, ONCT-534, which is being studied in patients with metastatic castration resistant cancer, did not show clinically meaningful improvements of disease
** There was one death related to complications of shock at the highest dose tested with ONCT-808
** While the strategic exploration is ongoing, co will discontinue all product development activities and will take other steps to reduce costs, including a workforce reduction to preserve cash resources
** Stock down 85% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。